Not Yet RecruitingNot Applicable

Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery

100 participantsStarted 2026-04-01

Plain-language summary

This study is to assess the benefits of goal-directed fluid management with ACUMEN in cardiac surgical patients and its impact on cardiac surgery-induced kidney injury.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients undergoing cardiopulmonary bypass * Procedure coronary artery bypass grafting, aortic valve replacement, or both Exclusion Criteria: * Patients \< 18 years old * Emergent surgery * Preoperative kidney disease (Cr \> 2.0 or on renal replacement therapy) * Ejection fraction \< 40% * Incomplete data in medical record

What they're measuring

Acute Kidney Injury

Timeframe: 7 days or discharge whichever occurs first

Renal Biomarkers

Timeframe: 48 hours postoperatively

Trial details

NCT IDNCT06109714

SponsorUniversity of Maryland, Baltimore

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-04-01

Contact for this trial

Reney A Henderson, MD

4103283961 rhenderson@som.umaryland.edu

View on ClinicalTrials.gov More Renal Injury trials